Literature DB >> 2906478

Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.

M C Rijk1, A van Schaik, J H van Tongeren.   

Abstract

Time-related urinary excretion and faecal excretion of 5-ASA and acetyl-5-ASA were measured in eight healthy volunteers after a single oral dose of the azo compounds sulphasalazine and olsalazine, the slow release compounds Pentasa, Asacol and Salofalk, and plain 5-ASA. After ingestion of both azo compounds and slow-release compounds, urinary excretion of 5-ASA was markedly delayed and reduced, and faecal excretion was enhanced. At all points of time, there was a significant, but not very marked difference in urinary excretion of 5-ASA after ingestion of the azo compounds and the slow-release compounds, in favour of the azo compounds. A significantly larger proportion of the ingested 5-ASA, moreover, was excreted in faeces after the intake of azo compounds as compared with slow-release compounds.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2906478     DOI: 10.3109/00365528809101550

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  4 in total

Review 1.  Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.

Authors:  A N Wadworth; A Fitton
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

2.  Amino acid derivatives of 5-ASA as novel prodrugs for intestinal drug delivery.

Authors:  C Clerici; G Gentili; E Boschetti; C Santucci; A G Aburbeh; B Natalini; R Pellicciari; A Morelli
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

Review 3.  Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases.

Authors:  Aleksandra Piechota-Polanczyk; Jakub Fichna
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-05-06       Impact factor: 3.000

Review 4.  Exploring Different Strategies for Efficient Delivery of Colorectal Cancer Therapy.

Authors:  Congcong Lin; Huei Leng Helena Ng; Weisan Pan; Hubiao Chen; Ge Zhang; Zhaoxiang Bian; Aiping Lu; Zhijun Yang
Journal:  Int J Mol Sci       Date:  2015-11-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.